GrupoPikolin, S.L. acquired 24.94% stake in Pangaea Oncology, S.A. from Mercantile Ebrosol Inversiones, S.L.U.
January 02, 2017
Share
GrupoPikolin, S.L. acquired 24.94% stake in Pangaea Oncology, S.A. (BME:PANG) from Mercantile Ebrosol Inversiones, S.L.U. on January 3, 2017. GrupoPikolin, S.L. acquired 2.64 million shares of Pangaea Oncology, S.A. As of October 23, 2016, the Real Decreto Legislativo approved the deal.
GrupoPikolin, S.L. completed the acquisition of 24.94% stake in Pangaea Oncology, S.A. (BME:PANG) from Mercantile Ebrosol Inversiones, S.L.U. on January 3, 2017.
Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Companyâs activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.